21 February, 2023
Hot Off The Press
Here are some information snippets for you from the promising world of Inherited Retinal Disease research:
- 3 small studies trialling voretigene neparvovec for RPE65 Retinitis Pigmentosa didn’t help acuity but did improve light sensitivity and patient mobility. Every little bit helps. (Study 1) (Study 2) (Study 3)
- A phase 1/2a optogenetics (MCO-010) trial for advanced RP, had good outcomes, which is unusual apparently with optogenetics. It also seemed safe which makes us optimistic. (Read more)
- There was an Anti VEG-F trial for wet AMD where 2 initial loading doses were given, after which the eye injections were given as deemed necessary on optical CT scan rather than routinely. This meant less injections for the patients, with just about the same outcomes. Interesting and could be the way of the future. (Read more)
- Six-month data from the phase 2 STARLIGHT optogenetic trial to restore vision in blind people with Stargardts should be available this year. (Read more)
- And another Stargardts trial, this time a Phase 3 clinical trial of a visual cycle modulator emixustat seems positive. (Read more)
That’s all for this edition folks.
Meanwhile, remember to keep eating a wide variety of whole foods and doing lots of exercise. These are the keys to strengthening the body’s resilience to all types of disease, inherited retinal disease included.